Refractory Hematologic Malignancy
7
3
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
14.3%
1 terminated out of 7 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
International Leukemia Target Board
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer